1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC).
Saved in:
| Title: | 1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). |
|---|---|
| Authors: | Eminowicz, G.1 (AUTHOR), Alexandre, J.2 (AUTHOR), Sanchez, L.M. Manso3 (AUTHOR), Braicu, I.4 (AUTHOR), Madry, R.5 (AUTHOR), Taskiran, C.6 (AUTHOR), Farolfi, A.7 (AUTHOR), Vulsteke, C.8 (AUTHOR), Hasegawa, K.9 (AUTHOR), Wang, J.10 (AUTHOR), Kim, J-W.11 (AUTHOR), Ananda, S.12 (AUTHOR), Tan, D.S.13 (AUTHOR), Crafton, S.14 (AUTHOR), Black, D.15 (AUTHOR), Slomovitz, B.M.16 (AUTHOR), Orlowski, R.J.17 (AUTHOR), Kruger, S.F.17 (AUTHOR), Yao, L.18 (AUTHOR), Monk, B.J.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS790-S790. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
